Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study

JOURNAL OF HEPATOCELLULAR CARCINOMA - Tập Volume 9 - Trang 157-170
Jingjun Huang1, Yongjian Guo1, Wensou Huang1, Xiaotao Hong2, Yi Quan3, Liteng Lin1, Jingwen Zhou1, Licong Liang1, Yaqin Zhang4, Juan Zhou5, Mingyue Cai1, Kangshun Zhu1
1Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, People's Republic of China
2Department of Interventional Medical Center, Jieyang People's Hospital, Jieyang City, Guangdong Province, People's Republic of China
3Department of Oncology Medical Center, The First People's Hospital of Zhaoqing, Zhaoqing City, Guangdong Province, People's Republic of China
4Department of Radiology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai City, Guangdong Province, People's Republic of China
5Department of Pharmacy, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, Guangdong Province, People's Republic of China

Tóm tắt

Từ khóa


Tài liệu tham khảo

Galle, 2018, J Hepatol, 69, 182, 10.1016/j.jhep.2018.03.019

Llovet, 2008, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857

Kudo, 2018, Lancet, 391, 1163, 10.1016/S0140-6736(18)30207-1

Bruix, 2017, Lancet, 389, 56, 10.1016/S0140-6736(16)32453-9

Abou-Alfa, 2018, N Engl J Med, 379, 54, 10.1056/NEJMoa1717002

Zhu, 2019, Lancet Oncol, 20, 282, 10.1016/S1470-2045(18)30937-9

Wang, 2020, Therap Adv Gastroenterol, 13, 1756284820932483, 10.1177/1756284820932483

El-Khoueiry, 2017, Lancet, 389, 2492, 10.1016/S0140-6736(17)31046-2

Zhu, 2018, Lancet Oncol, 19, 940, 10.1016/S1470-2045(18)30351-6

Finn, 2020, J Clin Oncol, 38, 193, 10.1200/JCO.19.01307

Bangaru, 2020, Aliment Pharmacol Ther, 51, 78, 10.1111/apt.15573

El-Khoueiry, 2021, J Clin Oncol, 39, 4078, 10.1200/JCO.2021.39.15_suppl.4078

Shigeta, 2020, J Immunother Cancer, 8, e001435, 10.1136/jitc-2020-001435

Ren, 2021, Lancet Oncol, 22, 977, 10.1016/S1470-2045(21)00252-7

Brahmer, 2010, J Clin Oncol, 28, 3167, 10.1200/JCO.2009.26.7609

Wang, 2019, MAbs, 11, 1443, 10.1080/19420862.2019.1654303

Marrero, 2018, Hepatology, 68, 723, 10.1002/hep.29913

Suner, 2020, Ann Med Surg, 58, 167, 10.1016/j.amsu.2020.08.042

National Cancer Institute. Common terminology criteria for adverse events, version 5.0; November 27, 2017. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50. Accessed December 16, 2020.

Eisenhauer, 2009, Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

Lencioni, 2010, Semin Liver Dis, 30, 52, 10.1055/s-0030-1247132

Wu, 2019, Clin Cancer Res, 25, 4530, 10.1158/1078-0432.CCR-18-2840

Bekir Hacioglu, 2020, J BUON, 25, 1897

Yoo, 2020, Liver Int, 40, 2263, 10.1111/liv.14496

Kim, 2020, Liver Int, 40, 2544, 10.1111/liv.14573

Casadei Gardini, 2017, Dig Liver Dis, 49, 943, 10.1016/j.dld.2017.04.022

Kudo, 2021, J Hepatol, 75, 600, 10.1016/j.jhep.2021.04.047

D’Alessio, 2021, Curr Opin Oncol, 33, 386, 10.1097/CCO.0000000000000744

Ameratunga, 2018, Eur J Cancer, 89, 56, 10.1016/j.ejca.2017.11.012

Dumitru, 2012, Cancer Immunol Immunother, 61, 1155, 10.1007/s00262-012-1294-5

Nagai, 2014, Transplantation, 97, 694, 10.1097/01.TP.0000437426.15890.1d

Xiao, 2014, BMC Cancer, 14, 117, 10.1186/1471-2407-14-117

Thông tin
Thông tin xuất bản

JOURNAL OF HEPATOCELLULAR CARCINOMA

Tập Volume 9

157-170

Thông tin tác giả